JP2005509623A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005509623A5 JP2005509623A5 JP2003535779A JP2003535779A JP2005509623A5 JP 2005509623 A5 JP2005509623 A5 JP 2005509623A5 JP 2003535779 A JP2003535779 A JP 2003535779A JP 2003535779 A JP2003535779 A JP 2003535779A JP 2005509623 A5 JP2005509623 A5 JP 2005509623A5
- Authority
- JP
- Japan
- Prior art keywords
- eye
- pharmaceutical composition
- gaba
- composition according
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 17
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 17
- 239000003085 diluting agent Substances 0.000 claims 8
- 230000012010 growth Effects 0.000 claims 8
- 239000000556 agonist Substances 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 6
- 230000000116 mitigating effect Effects 0.000 claims 5
- 230000009596 postnatal growth Effects 0.000 claims 5
- 230000003405 preventing effect Effects 0.000 claims 5
- 201000009487 Amblyopia Diseases 0.000 claims 4
- 206010020675 Hypermetropia Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000004305 hyperopia Effects 0.000 claims 4
- 201000006318 hyperopia Diseases 0.000 claims 4
- 230000004379 myopia Effects 0.000 claims 4
- 208000001491 myopia Diseases 0.000 claims 4
- 102000005915 GABA Receptors Human genes 0.000 claims 3
- 108010005551 GABA Receptors Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003140 4 aminobutyric acid A receptor blocking agent Substances 0.000 claims 2
- 239000003483 4 aminobutyric acid A receptor stimulating agent Substances 0.000 claims 2
- 239000003412 4 aminobutyric acid B receptor blocking agent Substances 0.000 claims 2
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 claims 2
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 claims 2
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims 2
- 229940121909 GABA receptor agonist Drugs 0.000 claims 2
- 229940098788 GABA receptor antagonist Drugs 0.000 claims 2
- 230000004323 axial length Effects 0.000 claims 2
- 210000001110 axial length eye Anatomy 0.000 claims 2
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical group NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 claims 1
- WBSMZVIMANOCNX-UHFFFAOYSA-N 3-amino-2-(4-chlorophenyl)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)(CN)C1=CC=C(Cl)C=C1 WBSMZVIMANOCNX-UHFFFAOYSA-N 0.000 claims 1
- XOESDNIUAWGCLU-UHFFFAOYSA-N 3-aminopropyl(cyclohexylmethyl)phosphinic acid Chemical group NCCCP(O)(=O)CC1CCCCC1 XOESDNIUAWGCLU-UHFFFAOYSA-N 0.000 claims 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical group OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims 1
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229960000794 baclofen Drugs 0.000 claims 1
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- MFUKVPOVVKKLRQ-UHFFFAOYSA-N methyl(1,2,3,6-tetrahydropyridin-1-ium-4-yl)phosphinate Chemical group CP(O)(=O)C1=CCNCC1 MFUKVPOVVKKLRQ-UHFFFAOYSA-N 0.000 claims 1
- 230000001722 neurochemical effect Effects 0.000 claims 1
- 230000008927 postnatal maturation Effects 0.000 claims 1
- 230000004515 progressive myopia Effects 0.000 claims 1
- SEYCKMQSPUVYEF-LURJTMIESA-N sch-50911 Chemical compound CC1(C)CO[C@@H](CC(O)=O)CN1 SEYCKMQSPUVYEF-LURJTMIESA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32965501P | 2001-10-16 | 2001-10-16 | |
| PCT/US2002/032776 WO2003032975A1 (en) | 2001-10-16 | 2002-10-16 | Modulation of ocular growth and myopia by gaba drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005509623A JP2005509623A (ja) | 2005-04-14 |
| JP2005509623A5 true JP2005509623A5 (https=) | 2006-01-05 |
Family
ID=23286413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535779A Pending JP2005509623A (ja) | 2001-10-16 | 2002-10-16 | Ｇａｂａ薬による目の成長及び近視の調節 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060264508A1 (https=) |
| EP (1) | EP1435938A4 (https=) |
| JP (1) | JP2005509623A (https=) |
| KR (1) | KR20040053181A (https=) |
| CN (1) | CN1604775A (https=) |
| CA (1) | CA2466800A1 (https=) |
| WO (1) | WO2003032975A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7266725B2 (en) | 2001-09-03 | 2007-09-04 | Pact Xpp Technologies Ag | Method for debugging reconfigurable architectures |
| DE19651075A1 (de) | 1996-12-09 | 1998-06-10 | Pact Inf Tech Gmbh | Einheit zur Verarbeitung von numerischen und logischen Operationen, zum Einsatz in Prozessoren (CPU's), Mehrrechnersystemen, Datenflußprozessoren (DFP's), digitalen Signal Prozessoren (DSP's) oder dergleichen |
| DE19654593A1 (de) | 1996-12-20 | 1998-07-02 | Pact Inf Tech Gmbh | Umkonfigurierungs-Verfahren für programmierbare Bausteine zur Laufzeit |
| DE19654595A1 (de) | 1996-12-20 | 1998-07-02 | Pact Inf Tech Gmbh | I0- und Speicherbussystem für DFPs sowie Bausteinen mit zwei- oder mehrdimensionaler programmierbaren Zellstrukturen |
| EP1329816B1 (de) | 1996-12-27 | 2011-06-22 | Richter, Thomas | Verfahren zum selbständigen dynamischen Umladen von Datenflussprozessoren (DFPs) sowie Bausteinen mit zwei- oder mehrdimensionalen programmierbaren Zellstrukturen (FPGAs, DPGAs, o.dgl.) |
| DE19654846A1 (de) | 1996-12-27 | 1998-07-09 | Pact Inf Tech Gmbh | Verfahren zum selbständigen dynamischen Umladen von Datenflußprozessoren (DFPs) sowie Bausteinen mit zwei- oder mehrdimensionalen programmierbaren Zellstrukturen (FPGAs, DPGAs, o. dgl.) |
| US6542998B1 (en) | 1997-02-08 | 2003-04-01 | Pact Gmbh | Method of self-synchronization of configurable elements of a programmable module |
| DE19704728A1 (de) | 1997-02-08 | 1998-08-13 | Pact Inf Tech Gmbh | Verfahren zur Selbstsynchronisation von konfigurierbaren Elementen eines programmierbaren Bausteines |
| DE19704742A1 (de) | 1997-02-11 | 1998-09-24 | Pact Inf Tech Gmbh | Internes Bussystem für DFPs, sowie Bausteinen mit zwei- oder mehrdimensionalen programmierbaren Zellstrukturen, zur Bewältigung großer Datenmengen mit hohem Vernetzungsaufwand |
| US8230411B1 (en) | 1999-06-10 | 2012-07-24 | Martin Vorbach | Method for interleaving a program over a plurality of cells |
| JP2004506261A (ja) | 2000-06-13 | 2004-02-26 | ペーアーツェーテー イクスペーペー テクノロジーズ アクチエンゲゼルシャフト | パイプラインｃｔプロトコルおよびｃｔ通信 |
| US8058899B2 (en) | 2000-10-06 | 2011-11-15 | Martin Vorbach | Logic cell array and bus system |
| AU2002220600A1 (en) | 2000-10-06 | 2002-04-15 | Pact Informationstechnologie Gmbh | Cell system with segmented intermediate cell structure |
| US6990555B2 (en) | 2001-01-09 | 2006-01-24 | Pact Xpp Technologies Ag | Method of hierarchical caching of configuration data having dataflow processors and modules having two- or multidimensional programmable cell structure (FPGAs, DPGAs, etc.) |
| US7844796B2 (en) | 2001-03-05 | 2010-11-30 | Martin Vorbach | Data processing device and method |
| US7210129B2 (en) | 2001-08-16 | 2007-04-24 | Pact Xpp Technologies Ag | Method for translating programs for reconfigurable architectures |
| US7444531B2 (en) | 2001-03-05 | 2008-10-28 | Pact Xpp Technologies Ag | Methods and devices for treating and processing data |
| US7581076B2 (en) | 2001-03-05 | 2009-08-25 | Pact Xpp Technologies Ag | Methods and devices for treating and/or processing data |
| US7996827B2 (en) | 2001-08-16 | 2011-08-09 | Martin Vorbach | Method for the translation of programs for reconfigurable architectures |
| US7434191B2 (en) | 2001-09-03 | 2008-10-07 | Pact Xpp Technologies Ag | Router |
| WO2003060747A2 (de) | 2002-01-19 | 2003-07-24 | Pact Xpp Technologies Ag | Reconfigurierbarer prozessor |
| EP2043000B1 (de) | 2002-02-18 | 2011-12-21 | Richter, Thomas | Bussysteme und Rekonfigurationsverfahren |
| JP2005533082A (ja) * | 2002-06-28 | 2005-11-04 | ノバルティス アクチエンゲゼルシャフト | 近視の治療のためのｇａｂａ−ｃレセプターアンタゴニストの使用 |
| US7657861B2 (en) | 2002-08-07 | 2010-02-02 | Pact Xpp Technologies Ag | Method and device for processing data |
| AU2003286131A1 (en) | 2002-08-07 | 2004-03-19 | Pact Xpp Technologies Ag | Method and device for processing data |
| WO2004038599A1 (de) | 2002-09-06 | 2004-05-06 | Pact Xpp Technologies Ag | Rekonfigurierbare sequenzerstruktur |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| FI20075498A7 (fi) * | 2007-06-29 | 2008-12-30 | Eero Castren | Menetelmä amblyopian hoitamiseksi masennuslääkkeillä |
| WO2015009533A1 (en) | 2013-07-16 | 2015-01-22 | Allergan, Inc. | Gabaa receptor antagonists affecting ganglion cell function and visual function |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| CN114306331B (zh) * | 2020-10-10 | 2023-07-18 | 远大生命科学(武汉)有限公司 | 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途 |
| KR102747804B1 (ko) * | 2024-03-07 | 2024-12-31 | 주식회사 케이에스비튜젠 | 라세탐 계열 화합물을 유효성분으로 포함하는 눈 기능 장애 예방, 개선 또는 치료용 조성물 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385939A (en) * | 1993-04-30 | 1995-01-31 | The Trustees Of The University Of Pennsylvania | GABA-ergic modulation of eye growth |
-
2002
- 2002-10-02 US US10/493,049 patent/US20060264508A1/en not_active Abandoned
- 2002-10-16 WO PCT/US2002/032776 patent/WO2003032975A1/en not_active Ceased
- 2002-10-16 EP EP02801699A patent/EP1435938A4/en not_active Withdrawn
- 2002-10-16 KR KR10-2004-7005660A patent/KR20040053181A/ko not_active Withdrawn
- 2002-10-16 CA CA002466800A patent/CA2466800A1/en not_active Abandoned
- 2002-10-16 JP JP2003535779A patent/JP2005509623A/ja active Pending
- 2002-10-16 CN CNA028251512A patent/CN1604775A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005509623A5 (https=) | ||
| Tham et al. | Phacoemulsification versus trabeculectomy in medically uncontrolled chronic angle-closure glaucoma without cataract | |
| Jacobi et al. | A comparative study of topical vs retrobulbar anesthesia in complicated cataract surgery | |
| Wei et al. | Adjunctive with versus without intravitreal bevacizumab injection before Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma | |
| Yazdani et al. | Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma | |
| Assaad et al. | Glaucoma drainage devices: pros and cons | |
| Soltau et al. | Changing paradigms in the medical treatment of glaucoma | |
| Kafkala et al. | Ahmed valve implantation for uncontrolled pediatric uveitic glaucoma | |
| De Feo et al. | Efficacy and safety of a steel drainage device implanted under a scleral flap | |
| JP2006524185A5 (https=) | ||
| CN116785286B (zh) | 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途 | |
| Coote et al. | Vascular changes after intra-bleb injection of bevacizumab | |
| Sebbag et al. | MicroPulse™ transscleral cyclophotocoagulation in the treatment of canine glaucoma: Preliminary results (12 dogs) | |
| Ghosh et al. | Combined diode laser cyclophotocoagulation and intravitreal bevacizumab (Avastin) in neovascular glaucoma | |
| Verma et al. | A comparative study of the duration and efficacy of tetracaine 1% and bupivacaine 0.75% in controlling pain following photorefractive keratectomy (PRK) | |
| JP2024041947A (ja) | 眼圧下降増強剤 | |
| EP0749303B1 (en) | Method of treating disorders of the eye | |
| Lai et al. | Latanoprost versus timolol gel to prevent ocular hypertension after phacoemulsification and intraocular lens implantation | |
| Kim et al. | Treatment of total hyphema with relatively low-dose tissue plasminogen activator | |
| Lane | Nepafenac: a unique nonsteroidal prodrug | |
| Gross et al. | Clinical experience with apraclonidine 0.5% | |
| US20040078009A1 (en) | Method and apparatus for the treatment of presbyopia and other eye disorders combining pharmocological and surgical means | |
| Ryoo et al. | Regression of iris neovascularization after subconjunctival injection of bevacizumab | |
| Patel et al. | Bilateral cystoid macular edema after bimatoprost implants | |
| Mendelsohn et al. | Secondary angle-closure glaucoma after central retinal vein occlusion |